Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22034009 | 0.79 | MEN1 (0.41) | SMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL15263236 | 0.73 | FFAR1 (0.38) | SMN1; SMN2ALDH1A1KDM4EL3MBTL1TDP1 | |
| SCHEMBL11060568 | 0.73 | FFAR1 (0.38) | SMN1; SMN2ALDH1A1KDM4EL3MBTL1TDP1 | |
| SCHEMBL2956414 | 0.72 | SIGMAR1 (0.40) | SMN1; SMN2ALDH1A1MAPTKDM4E | |
| SCHEMBL40197 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPTKDM4ETDP1 | |
| SCHEMBL16401965 | 0.72 | MEN1 (0.31) | ALDH1A1L3MBTL1 | |
| SCHEMBL1003534 | 0.72 | MEN1 (0.31) | ALDH1A1L3MBTL1 | |
| SCHEMBL22321638 | 0.72 | MEN1 (0.31) | L3MBTL1 | |
| SCHEMBL2121005 | 0.72 | CHRM2 (0.41) | CYP1A2ALDH1A1ALOX15 | |
| SCHEMBL2174381 | 0.72 | CHRM2 (0.41) | CYP1A2ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120803-A1 | 3,4-DIHYDROQUINAZOLINE DERIVATIVES | DONGWOO SYNTECH CO., LTD. (KR) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120803-A1 | 3,4-DIHYDROQUINAZOLINE DERIVATIVES | CACNA1I, CACNA1G, CACNA1H | HRH3 1277/4885CYP1A2 1720/4885MAPK1 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.